Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for celg
119.16
-1.71 (-1.41%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 118.89 - 124.29
52 week 66.85 - 124.60
Open 119.49
Vol / Avg. 8.13M/5.98M
Mkt cap 95.17B
P/E 49.72
Div/yield     -
EPS 2.40
Shares 798.70M
Beta 1.10
Inst. own 83%
Apr 22, 2015
Q1 2015 Celgene Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 24, 2015
Celgene Corp at RBC Healthcare Conference - 8:00AM EST - Add to calendar
Feb 11, 2015
Celgene Corp at Leerink Global Healthcare Conference - 11:30AM EST - Add to calendar
Jan 29, 2015
Q4 2014 Celgene Corp Earnings Release
Jan 29, 2015
Q4 2014 Celgene Corp Earnings Call
Jan 12, 2015
Celgene Corp at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2015
Celgene Corp at JPMorgan Healthcare Conference - Webcast
Jan 12, 2015
Preliminary 2014 Celgene Corp Earnings Release
Dec 7, 2014
Celgene Presentation at the American Society of Hematology - Webcast
Nov 11, 2014
Celgene Corp at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 29.44% 26.07%
Operating margin 36.04% 32.84%
EBITD margin - 36.84%
Return on average assets - -
Return on average equity - -
Employees 5,100 -
CDP Score - 80 C

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company�s commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST/IMNOVID, THALOMID, ISTODAX and azacitidine for injection. The Company�s preclinical and clinical-stage pipeline includes Oral anti-inflammatory agents, OTEZLA (apremilast); Next generation thalidomide analogues, CC-122 and CC-220; Cellular therapies, PDA-001 and PDA-002; CC-486; Sotatercept and ACE-536; mTOR pathway inhibitors, CC-223 and CC-115; Epigenetic modifiers, EPZ-5676 and CC-292. Its subsidiaries are Celgene Avilomics Research and Celgene Cellular Therapeutics. The Company collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept and ACE-536 to treat anemia in patients with rare blood disorders.

Officers and directors

Robert J. Hugin Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark J. Alles President, Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Jacqualyn A. Fouse Ph.D. President - Hematology & Oncology
Age: 52
Bio & Compensation  - Reuters
Tuomo Patsi President - Europe, Middle East and Africa (EMEA)
Bio & Compensation  - Reuters
Scott Smith President - Inflammation & Immunology
Bio & Compensation  - Reuters
Perry A. Karsen Chief Operations Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Lawrence V. Stein Executive Vice President, General Counsel, Corporate Secretary
Age: 64
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Executive Vice President, President - Research and Early Development
Age: 60
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 68
Bio & Compensation  - Reuters